世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000034864

変形性関節症市場

Fatpos Global

Osteoarthritis Market

発刊日 2023/04

言語英語

体裁Word-PDF

ライセンス/価格

0000034864

Excel
Single
Multi
Global

※170-350ページ
※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。電子媒体での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

変形性関節症の市場規模、シェア、および分析、種類別(変形性股関節症、変形性膝関節症、足と足首の変形性関節症、変形性肩関節症、脊椎変形性関節症)、薬剤の種類別(鎮痛剤、コルチコステロイド、粘性補充剤、非ステロイド性抗炎症薬{NSAIDS}) 、診断別(イメージングと関節液分析)、投与経路別(非経口経路、経口経路、局所経路)、治療別(投薬、治療、手術)、流通経路別(院内薬局、Eコマース、小売薬局、ドラッグ ストア)、購入パターン別 (処方薬、OTC医薬品) および地域別予測、2022 〜 2032

市場概要

変形性関節症市場は2022年から2032年の予測期間中9.0%のCAGRで成長すると予想されます。

変形性関節症市場は、予測期間中 9.0% の CAGR で 150 億ドルに達する見込みです。これは、変形性関節症についての意識が高まり、高度な治療へのアクセスが変形性関節症治療の成長を後押ししているためです。低侵襲の非外科的治療に対する需要の高まりが、変形性関節症市場の成長を促しています。

レポート詳細

目次

1 Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Osteoarthritis Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot

2 Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation

3 Market Characteristics
3.1. Market Definition
3.2. Osteoarthritis Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data

4 Osteoarthritis Market - Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability

5 Macroeconomic Indicators

6 Recent Developments

7 Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends

8 Risk Analysis

9 Market Analysis
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological

10 Osteoarthritis Market
10.1. Overview
10.2. Historical Analysis (2016-2020)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

11 Osteoarthritis Market Size & Forecast 2022A-2032F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Type
11.3.1.1. Hip Osteoarthritis
11.3.1.1.1. By Value (USD Million) 2022-2032F
11.3.1.1.2. Market Share (%) 2022-2032F
11.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.2. Knee Osteoarthritis
11.3.1.2.1. By Value (USD Million) 2022-2032F
11.3.1.2.2. Market Share (%) 2022-2032F
11.3.1.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.3. Foot & Ankle Osteoarthritis
11.3.1.3.1. By Value (USD Million) 2022-2032F
11.3.1.3.2. Market Share (%) 2022-2032F
11.3.1.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.4. Shoulder Osteoarthritis
11.3.1.4.1. By Value (USD Million) 2022-2032F
11.3.1.4.2. Market Share (%) 2022-2032F
11.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.5. Spinal Osteoarthritis
11.3.1.5.1. By Value (USD Million) 2022-2032F
11.3.1.5.2. Market Share (%) 2022-2032F
11.3.1.5.3. Y-o-Y Growth (%) 2022-2032F
11.3.2. By Drug Type
11.3.2.1. Analgesics
11.3.2.1.1. By Value (USD Million) 2022-2032F
11.3.2.1.2. Market Share (%) 2022-2032F
11.3.2.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.2. Corticosteroids
11.3.2.2.1. By Value (USD Million) 2022-2032F
11.3.2.2.2. Market Share (%) 2022-2032F
11.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.3. Viscosupplementation agents
11.3.2.3.1. By Value (USD Million) 2022-2032F
11.3.2.3.2. Market Share (%) 2022-2032F
11.3.2.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.4. Nonsteroidal anti-inflammatory drugs {NSAIDS}
11.3.2.4.1. By Value (USD Million) 2022-2032F
11.3.2.4.2. Market Share (%) 2022-2032F
11.3.2.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.3. By Diagnosis
11.3.3.1. Imagining
11.3.3.1.1. By Value (USD Million) 2022-2032F
11.3.3.1.2. Market Share (%) 2022-2032F
11.3.3.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.3.2. Joint Fluid Analysis
11.3.3.2.1. By Value (USD Million) 2022-2032F
11.3.3.2.2. Market Share (%) 2022-2032F
11.3.3.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.4. By Route of Administration
11.3.4.1. Parenteral Route
11.3.4.1.1. By Value (USD Million) 2022-2032F
11.3.4.1.2. Market Share (%) 2022-2032F
11.3.4.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.4.2. Oral Route
11.3.4.2.1. By Value (USD Million) 2022-2032F
11.3.4.2.2. Market Share (%) 2022-2032F
11.3.4.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.4.3. Topical Route
11.3.4.3.1. By Value (USD Million) 2022-2032F
11.3.4.3.2. Market Share (%) 2022-2032F
11.3.4.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.5. By Treatment
11.3.5.1. Medication
11.3.5.1.1. By Value (USD Million) 2022-2032F
11.3.5.1.2. Market Share (%) 2022-2032F
11.3.5.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.5.2. Therapy
11.3.5.2.1. By Value (USD Million) 2022-2032F
11.3.5.2.2. Market Share (%) 2022-2032F
11.3.5.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.5.3. Surgery
11.3.5.3.1. By Value (USD Million) 2022-2032F
11.3.5.3.2. Market Share (%) 2022-2032F
11.3.5.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.6. By Distribution Channel
11.3.6.1. Hospitals Pharmacy
11.3.6.1.1. By Value (USD Million) 2022-2032F
11.3.6.1.2. Market Share (%) 2022-2032F
11.3.6.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.6.2. E-Commerce
11.3.6.2.1. By Value (USD Million) 2022-2032F
11.3.6.2.2. Market Share (%) 2022-2032F
11.3.6.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.6.3. Retail Pharmacy
11.3.6.3.1. By Value (USD Million) 2022-2032F
11.3.6.3.2. Market Share (%) 2022-2032F
11.3.6.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.6.4. Drug Store
11.3.6.4.1. By Value (USD Million) 2022-2032F
11.3.6.4.2. Market Share (%) 2022-2032F
11.3.6.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.7. By Purchasing Pattern
11.3.7.1. Prescription Drugs
11.3.7.1.1. By Value (USD Million) 2022-2032F
11.3.7.1.2. Market Share (%) 2022-2032F
11.3.7.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.7.2. Over-The-Counter Drugs
11.3.7.2.1. By Value (USD Million) 2022-2032F
11.3.7.2.2. Market Share (%) 2022-2032F
11.3.7.2.3. Y-o-Y Growth (%) 2022-2032F

12 North America Osteoarthritis Market Size & Forecast 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Type
12.3.2. By Drug Type
12.3.3. By Diagnosis
12.3.4. By Route of Administration
12.3.5. By Treatment
12.3.6. By Distribution Channel
12.3.7. By Purchasing Pattern
12.4. Country
12.4.1. United States
12.4.2. Canada

13 Europe Osteoarthritis Market Size & Forecast 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Type
13.3.2. By Drug Type
13.3.3. By Diagnosis
13.3.4. By Route of Administration
13.3.5. By Treatment
13.3.6. By Distribution Channel
13.3.7. By Purchasing Pattern
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)

14 Asia Osteoarthritis Market Size & Forecast 2022A-2032F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Type
14.3.2. By Drug Type
14.3.3. By Diagnosis
14.3.4. By Route of Administration
14.3.5. By Treatment
14.3.6. By Distribution Channel
14.3.7. By Purchasing Pattern
14.4. By Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC

15 Middle East and Africa Osteoarthritis Market Size & Forecast 2022A-2032F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Type
15.3.2. By Drug Type
15.3.3. By Diagnosis
15.3.4. By Route of Administration
15.3.5. By Treatment
15.3.6. By Distribution Channel
15.3.7. By Purchasing Pattern
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa

16 Latin America Osteoarthritis Market Size & Forecast 2022A-2032F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Type
16.3.2. By Drug Type
16.3.3. By Diagnosis
16.3.4. By Route of Administration
16.3.5. By Treatment
16.3.6. By Distribution Channel
16.3.7. By Purchasing Pattern
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America

17 Competitive Landscape
17.1. Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders

18 Company Profiles
18.1. Pfizer Inc
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. Abbott
18.3. Novartis AG
18.4. Eli Lilly and Company
18.5. Bayer AG
18.6. Johnson & Johnson
18.7. ABIOGEN PHARMA S.p.A
18.8. Merck Sharp & Dohme Corp.
18.9. Apotex Inc.
18.10. TissueGene Inc.
18.11. Ampio Pharmaceuticals Inc.
18.12. Mylan N.V.
18.13. Tolmar Pharmaceuticals, Inc.
18.14. Other Prominent Players

19 Appendix

20 Consultant Recommendation

この商品のレポートナンバー

0000034864

TOP